AU2025271036A1 — Drug eluting ocular implant
Assigned to Glaukos Corp · Expires 2025-12-11 · 0y expired
What this patent protects
90 An ocular implant configured to deliver a drug within an eye of a subject, the ocular implant comprising: an outer shell shaped to define an interior space, the outer shell comprising an opening; a cap positioned at a proximal end of the outer shell; a drug disposed within the…
USPTO Abstract
90 An ocular implant configured to deliver a drug within an eye of a subject, the ocular implant comprising: an outer shell shaped to define an interior space, the outer shell comprising an opening; a cap positioned at a proximal end of the outer shell; a drug disposed within the interior space of the outer shell; a permeable or semi-permeable material being permeable or semi-permeable to the drug so as to facilitate controlled elution of the drug; and an anchor configured to affix a distal tip of the ocular implant into scleral tissue of the eye, wherein at least a portion of the anchor is configured to extend into the scleral tissue, wherein the drug is travoprost.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.